New drug combo aims to shrink stomach cancer before surgery

NCT ID NCT07493382

Not yet recruiting Disease control Sponsor: Tianjin Medical University Cancer Institute and Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests whether adding an experimental immunotherapy drug (Retlirafusp alfa) to standard chemotherapy can improve outcomes for people with gastroesophageal junction adenocarcinoma. About 30 patients will receive the drug combination before surgery, and some may continue the immunotherapy afterward. The main goal is to see how many patients have no cancer left at the time of surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Retlirafusp alfa (an experimental immunotherapy drug) combined with chemotherapy (capecitabine and oxaliplatin)
What this could lead to: If successful, this could point toward a more effective treatment approach for gastroesophageal junction cancer, potentially improving tumor shrinkage before surgery and delaying recurrence afterward.
What could go wrong: This is a very early, small (30 people), single-arm phase II trial with no comparison group. The drug may not work better than standard chemo, and side effects from the combination could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GEJ ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GEJ ADENOCARCINOMA

More trials for these conditions

Other studies related to the condition(s) this trial covers.